MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Matinas BioPharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.66−0.71 (-29.96%)
Close on Oct 19, 2026
- Market cap
- $10.63M
- P/E (TTM)
- –
- Dividend yield
- –
Matinas BioPharma statistics
Financials through Dec 31, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Matinas BioPharma | Industry median |
|---|---|---|
| Market Cap | $24.39M | $166.30M |
| Enterprise Value | $24.39M | $88.19M |
Efficiency
| Measure | Matinas BioPharma | Industry median |
|---|---|---|
| Employee Count | 2 | 74 |
Shares
| Measure | Matinas BioPharma | Industry median |
|---|---|---|
| Shares Outstanding | 14,692,800 | 58,127,000 |
Calculated by StockData from Matinas BioPharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.